NCT00304460View on ClinicalTrials.gov

Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 13, 2006

Primary Completion Date

February 27, 2014

Study Completion Date

February 27, 2014

Conditions
Metastatic MelanomaRenal Cell Cancer
Interventions
BIOLOGICAL

aldesleukin

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00304460 - Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | Biotech Hunter | Biotech Hunter